ONCOTHERAPY SCIENCE, INC.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2001-04-06
- Employees
- 54
- Market Cap
- -
- Website
- http://www.oncotherapy.co.jp
Clinical Trials
19
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
- Conditions
- Relapsed or Refractory Synovial Sarcoma
- Interventions
- Drug: OTSA101-DTPA-111InDrug: OTSA101-DTPA-90Y
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04176016
- Locations
- 🇯🇵
Osaka International Cancer Institute, Osaka, Japan
🇯🇵Cancer Institute Hospital of JFCR, Tokyo, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
Safety Study of MELK Inhibitor to Treat Patients with Advanced Breast Cancer and Triple Negative Breast Cancer
- Conditions
- Relapsed/refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02926690
- Locations
- 🇺🇸
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Weill Cornell Medicine | NewYork-Presbyterian, New York, New York, United States
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
- Conditions
- AMLAdvanced MDSALLAdvanced CMLAdvanced MPNs
- Interventions
- Drug: OTS167IV
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02795520
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects
- Conditions
- Healthy
- Interventions
- Other: Cherry syrupDrug: OTS167IV
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02768519
- Locations
- 🇦🇺
CMAX, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Phase 1 Study of OTS167 in Patients With Solid Tumors
- Conditions
- Metastatic TumorsSolid Tumors
- Interventions
- Drug: OTS167IV
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01910545
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States